Switzerlandhoboken

LACHEN, Switzerland and HOBOKEN, New Jersey - - ISTH Symposia Discuss Prevention and Eradication of FVIII Inhibitors and Introduce First Recombinant FVIII Produced From a Human Cell Line Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors.